SHPG : Summary for Shire plc - American Depositary - Yahoo Finance

U.S. Markets closed

Shire plc (SHPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
164.80-7.97 (-4.61%)
At close: 4:00 PM EST

167.43 2.63 (1.60%)
After hours: 5:18 PM EST

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close172.77
Bid148.01 x 200
Ask167.35 x 300
Day's Range163.46 - 169.30
52 Week Range147.60 - 210.33
Avg. Volume1,303,660
Market Cap49.66B
PE Ratio (TTM)251.99
Earnings DateN/A
Dividend & Yield0.80 (0.46%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Accesswire2 days ago

    Blog Coverage Shire Announced Successful Results of its Phase III Investigational Study of VONVENDI(TM)

    Upcoming AWS Coverage on Impax Laboratories Post-Earnings Results LONDON, UK / ACCESSWIRE / December 5, 2016 / Active Wall St. blog coverage looks at the headline from Shire PLC (NASDAQ: SHPG ) as the ...

  • 5 Healthcare Stocks Billionaires Love The Most
    Insider Monkey3 days ago

    5 Healthcare Stocks Billionaires Love The Most

    The election of Donald Trump has heralded an era of optimism in the healthcare industry, which has been one of the worst performing sectors over the past two years. The Don is expected to ease regulations in the healthcare sector and bulls see solid prospects for the sector ahead. In this article we take a look […]

  • PR Newswire5 days ago

    Shire Reports on Four Decades of Real-World Safety Experience With FEIBA®

    Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update on its safety database describing 40 years of real-world experience with the bypassing agent FEIBA [Anti-Inhibitor Coagulant Complex]. Shire also revealed new in vitro data showing the potential for excessive thrombin generation when combining an investigational procoagulant bispecific antibody and bypass therapy for breakthrough bleeds. Recently, concerns have emerged related to the use of an investigational non-factor product when combined with marketed bypassing agents for hemophilia patients with inhibitors.